This article is more than 5 years old. Information may no longer be current.

Less conjunctival hyperemia found with latanoprost use than bimatoprost, travoprost

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

CHARLESTON, S.C. — Healthy eyes were shown to have significantly less short-term conjunctival hyperemia when treated with latanoprost than healthy eyes treated with bimatoprost or travoprost, researchers here with the Pharmaceutical Research Corp. say.

William C. Stewart, MD, and colleagues randomized 28 healthy eyes to receive latanoprost 0.005%, bimatoprost 0.03% and travoprost 0.004%. Conjunctival hyperemia was evaluated at the 24-hour trough and at hour 1 after dosing. Each eye was crossed over between periods after a 1-week washout interval.

Hyperemia was measured by standard photographic measure at the slit lamp and by anterior segment photographs after dosing for 5 days.

At the 24-hour trough, latanoprost had significantly less hyperemia than bimatoprost; at hour 1 latanoprost had significantly less hyperemia than travoprost as well. After hour 1, latanoprost had less change in hyperemia than bimatoprost or travoprost between the study and the non-study eye.

The study is published in the March issue of American Journal of Ophthalmology.